Agenus Inc
Research Agenus Inc (AGEN) on Bullrun: market cap USD 326.86M, P/E 2.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGEN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 326.86M
- P/E2.9
- Financial periodQ2 2026
- RevenueUSD 34.52M
- Net income-USD 550.00K
- Free cash flow-USD 31.20M
- Gross margin57.2%
Valuation Snapshot
latest market cap is USD 326.86M; P/E is 2.9.
Peer valuation comparison
Latest P/E is 2.89x versus a Healthcare sector median of 24.61x (88.2% below).
Latest P/E is 2.89x versus a United States median of 23.85x (87.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 114.20M | -USD 3.08M | -USD 77.20M | 99.1% | 0 | USD 3.00M | USD 44.66M | -USD 271.11M |
| FY2024 | USD 103.46M | -USD 232.27M | -USD 158.89M | 99.5% | -10.59 | USD 40.44M | USD 33.17M | -USD 326.38M |
| FY2023 | USD 156.31M | -USD 257.44M | -USD 234.16M | 98.0% | -13.75 | USD 76.11M | USD 12.91M | -USD 160.33M |
| FY2022 | USD 98.02M | -USD 230.66M | -USD 228.44M | 89.2% | -15.64 | USD 178.67M | USD 13.16M | -USD 61.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 326.86M | 2.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 110.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 64.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 316.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 717.98M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 811.80M | n/a | n/a | n/a |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Agenus Inc's market cap?
Agenus Inc's market capitalization is USD 326.86M.
What is Agenus Inc's P/E ratio?
Agenus Inc's price-to-earnings (P/E) ratio is 2.9.
What does Agenus Inc do?
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.